article thumbnail

Antimicrobial Stewardship in the United kingdom: Perspective From A Pharmacist At A Bone & Joint Hospital

IDStewardship

I moved to the southeast and spent my early career working in district general hospitals. During my postgraduate Clinical Pharmacy Diploma, I gravitated towards antimicrobial stewardship whilst working in critical care. In England, AMS targets are built into all National Health Services (NHS) hospital contracts.

Hospitals 147
article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

The COVID-19 pandemic underscores the importance of DHTs through the increased reliance on telemedicine services and remote patient monitoring programs to ensure patient safety and triage scarce hospital resources. Insulin delivery is independent of insulin management system. IMDRF SaMD Risk Categorization. Framework 26. Framework 28.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sebelipase alfa becomes first NHS treatment for Wolman disease after NICE recommendation

Hospital Pharmacy Europe

NICE’s recommendation is based on sebelipase alfa’s clinical effectiveness evidence from two single-arm, open-label, multicentre trials: LAL-CL08 and LAL-CL03. A natural history study (LAL-1-NH01) was also used to estimate outcomes for clinical management without sebelipase alfa.

article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

The COVID-19 pandemic underscores the importance of DHTs through the increased reliance on telemedicine services and remote patient monitoring programs to ensure patient safety and triage scarce hospital resources. Insulin delivery is independent of insulin management system. IMDRF SaMD Risk Categorization. Framework 26. Framework 28.

article thumbnail

The Incredible Shrinking Exemption: FDA Final CDS Guidance Would Significantly Narrow the Scope of Exempt Clinical Decision Support Software Under the Cures Act

The FDA Law Blog

The final guidance therefore may have significant implications for a wide range of stakeholders, including not only software developers but also health care providers, hospitals, patients and payors. The final guidance focuses on labeling as a means to effectuate Criterion 4. software or labeling.

FDA 52